Leerink Partnrs Brokers Raise Earnings Estimates for Beigene

Beigene, Ltd. (NASDAQ:ONC) – Equities researchers at Leerink Partnrs increased their FY2024 EPS estimates for Beigene in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($5.51) per share for the year, up from their previous forecast of ($5.98). The consensus estimate for Beigene’s current full-year earnings is ($5.83) per share. Leerink Partnrs also issued estimates for Beigene’s Q4 2024 earnings at ($0.82) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.46 EPS, FY2025 earnings at $0.14 EPS, FY2026 earnings at $7.33 EPS and FY2027 earnings at $12.83 EPS.

Beigene Trading Down 1.7 %

Shares of ONC opened at $219.67 on Monday. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $21.47 billion, a price-to-earnings ratio of -26.66 and a beta of 0.63. Beigene has a one year low of $126.97 and a one year high of $248.16.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.